We are encouraged by what this preliminary look at the data from this study has shown us
Madison, WI (Vocus) June 25, 2010
Quincy Bioscience, a research-based biotechnology company, announced interim results from the Prevagen Memory Study. The Prevagen Memory Study is a three-month long, randomized, double-blind, placebo controlled study using both qualitative Quality of Life surveys and a quantitative, computer-based set of cognitive tests developed by Cogstate Ltd.
Prevagen showed statistically significant improvement over placebo at Day 60 in measures of spatial working memory and executive function in thirty five generally healthy adults reporting memory concerns prior to the start of the trial. The Prevagen arm showed a 14% reduction in the number of total errors compared to Day 0. The average age of this initial cohort was 61 years old and sixty eight percent of the participants were female. A statistically significant improvement was also seen in the change from baseline (Day 0) measurements. “We are encouraged by what this preliminary look at the data from this study has shown us,” said KC Lerner, Manager of Business Development.
Prevagen contains the calcium-binding protein apoaequorin. Apoaequorin has demonstrated neuroprotection in pre-clinical studies performed at the University of Wisconsin-Milwaukee. Apoaequorin was originally isolated from Aequorea victoria, a species of jellyfish found in the Puget Sound.
“The relationship between intracellular calcium imbalance and age-related cognitive decline is well-established. The data shows that Prevagen is a new tool for staying cognitively fit as we age. With 78 million baby boomers getting older every day, helping people with memory concerns is our first priority,” said Quincy Bioscience President Mark Underwood. Quincy Bioscience is also looking at several health conditions that are believed to be the result of disruptions in calcium homeostasis and intends to study the effect of Prevagen in these conditions.
About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.